Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase I Study of Immune-Enabling Antibody Therapy CMTX-101

Clarametyx Biosciences Inc. announced that the FDA has accepted the company’s IND application to initiate a first-in-human Phase I safety study followed by a Phase Ib trial of CMTX-101, a novel immune-enabling antibody therapy.